CR20120476A - Formulaciones orales y sales lipofílicas de metilnaltrexona - Google Patents

Formulaciones orales y sales lipofílicas de metilnaltrexona

Info

Publication number
CR20120476A
CR20120476A CR20120476A CR20120476A CR20120476A CR 20120476 A CR20120476 A CR 20120476A CR 20120476 A CR20120476 A CR 20120476A CR 20120476 A CR20120476 A CR 20120476A CR 20120476 A CR20120476 A CR 20120476A
Authority
CR
Costa Rica
Prior art keywords
methylntrexone
lipophylic
salts
oral formulations
formulations
Prior art date
Application number
CR20120476A
Other languages
English (en)
Spanish (es)
Inventor
Syed M Shah
Christopher Richard Diorio
Eric C Ehrnsperger
Xu Meng
Shareffi Kadum A Al
Jonathan Marc Cohen
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44148539&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20120476(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of CR20120476A publication Critical patent/CR20120476A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CR20120476A 2010-03-11 2012-09-19 Formulaciones orales y sales lipofílicas de metilnaltrexona CR20120476A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31301810P 2010-03-11 2010-03-11

Publications (1)

Publication Number Publication Date
CR20120476A true CR20120476A (es) 2012-11-30

Family

ID=44148539

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20120476A CR20120476A (es) 2010-03-11 2012-09-19 Formulaciones orales y sales lipofílicas de metilnaltrexona

Country Status (32)

Country Link
US (8) US8524276B2 (cg-RX-API-DMAC7.html)
EP (2) EP3178472B1 (cg-RX-API-DMAC7.html)
JP (4) JP6143409B2 (cg-RX-API-DMAC7.html)
KR (2) KR101913102B1 (cg-RX-API-DMAC7.html)
CN (2) CN102918039B (cg-RX-API-DMAC7.html)
AR (1) AR080491A1 (cg-RX-API-DMAC7.html)
AU (1) AU2011224275B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012022873B1 (cg-RX-API-DMAC7.html)
CA (1) CA2789798C (cg-RX-API-DMAC7.html)
CL (1) CL2012002192A1 (cg-RX-API-DMAC7.html)
CO (1) CO6630134A2 (cg-RX-API-DMAC7.html)
CR (1) CR20120476A (cg-RX-API-DMAC7.html)
EA (1) EA029096B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP12012208A (cg-RX-API-DMAC7.html)
ES (1) ES2623926T3 (cg-RX-API-DMAC7.html)
GE (1) GEP201606550B (cg-RX-API-DMAC7.html)
GT (1) GT201200247A (cg-RX-API-DMAC7.html)
HU (1) HUE033133T2 (cg-RX-API-DMAC7.html)
IL (1) IL221452A (cg-RX-API-DMAC7.html)
MA (1) MA34146B1 (cg-RX-API-DMAC7.html)
MX (2) MX368805B (cg-RX-API-DMAC7.html)
MY (1) MY160727A (cg-RX-API-DMAC7.html)
NZ (3) NZ601595A (cg-RX-API-DMAC7.html)
PE (1) PE20130063A1 (cg-RX-API-DMAC7.html)
PH (1) PH12012501622A1 (cg-RX-API-DMAC7.html)
PL (2) PL3178472T3 (cg-RX-API-DMAC7.html)
SG (3) SG10201606618PA (cg-RX-API-DMAC7.html)
TN (1) TN2012000392A1 (cg-RX-API-DMAC7.html)
TW (2) TWI589293B (cg-RX-API-DMAC7.html)
UA (2) UA123856C2 (cg-RX-API-DMAC7.html)
WO (1) WO2011112816A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201808498B (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2528631T3 (es) 2003-04-08 2015-02-11 Progenics Pharmaceuticals, Inc. Formulaciones farmacéuticas que contienen metilnaltrexona
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
ES2765811T5 (es) 2007-03-29 2024-02-27 Progenics Pharm Inc Forma cristalina de bromuro de (R)-n-metilnaltrexona y sus usos
US9061076B2 (en) 2007-05-25 2015-06-23 North Carolina State University Viral nanoparticle cell-targeted delivery platform
KR101913102B1 (ko) 2010-03-11 2018-10-31 와이어쓰 엘엘씨 메틸날트렉손의 경구 제형 및 친유성 염
US8627816B2 (en) 2011-02-28 2014-01-14 Intelliject, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
US8939943B2 (en) 2011-01-26 2015-01-27 Kaleo, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
US20130317050A1 (en) * 2011-12-19 2013-11-28 Enoch Bortey Methods for treatment and prevention of opioid induced constipation using oral compositions of methylnaltrexone
WO2015191686A1 (en) * 2014-06-10 2015-12-17 Salix Pharmaceuticals, Inc. Methods of administering methylnaltrexone
US9642848B2 (en) * 2014-07-08 2017-05-09 Insys Development Company, Inc. Sublingual naloxone spray
US10722510B2 (en) * 2014-07-08 2020-07-28 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
US10441538B2 (en) * 2014-07-08 2019-10-15 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
US11135155B2 (en) 2014-07-08 2021-10-05 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
US10617686B2 (en) * 2014-07-08 2020-04-14 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
CN107249327A (zh) 2014-10-17 2017-10-13 萨利克斯药品公司 使用甲基纳曲酮减缓肿瘤进展
US20220062183A1 (en) * 2018-12-19 2022-03-03 Friulchem S.P.A. Process for the manufacture of a tablet of rifaximin and tablet of rifaximin
EP3965731A1 (en) * 2019-05-07 2022-03-16 Bausch Health Ireland Limited Liquid oral dosage formulations of methylnaltrexone
CA3142214A1 (en) 2019-06-03 2020-12-10 Bausch Health Ireland Limited Use of methylnaltrexone and rifaximin for treatment of increased gut permeability or associated disorders
EP4142727A1 (en) 2020-05-02 2023-03-08 Bausch Health Ireland Limited Methods of reducing mortality risk in subjects suffering from an underlying disease or condition by administration of methylnaltrexone
WO2023031955A1 (en) * 2021-08-28 2023-03-09 Redasani Vijayendrakumar Virendrakumar Ji Oral pharmaceutical compositions of methylnaltrexone and salt thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4176186A (en) 1978-07-28 1979-11-27 Boehringer Ingelheim Gmbh Quaternary derivatives of noroxymorphone which relieve intestinal immobility
US4861781A (en) 1986-03-07 1989-08-29 The University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
US4719215A (en) 1986-03-07 1988-01-12 University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
CA1297218C (en) 1986-03-14 1992-03-10 Edward David Weil Thermally stable diphosphonate-type flame retardant additive for plastics
US5102887A (en) 1989-02-17 1992-04-07 Arch Development Corporation Method for reducing emesis and nausea induced by the administration of an emesis causing agent
US5780012A (en) 1990-06-21 1998-07-14 Huland; Edith Method for reducing lung afflictions by inhalation of cytokine solutions
WO1994008599A1 (en) 1992-10-14 1994-04-28 The Regents Of The University Of Colorado Ion-pairing of drugs for improved efficacy and delivery
US5866154A (en) 1994-10-07 1999-02-02 The Dupont Merck Pharmaceutical Company Stabilized naloxone formulations
DE19651551C2 (de) 1996-12-11 2000-02-03 Klinge Co Chem Pharm Fab Opioidantagonisthaltige galenische Formulierung
WO1998035679A1 (de) 1997-02-14 1998-08-20 Gödecke Aktiengesellschaft Stabilisierung von naloxonhydrochlorid
ATE210983T1 (de) 1997-11-03 2002-01-15 Stada Arzneimittel Ag Stabilisiertes kombinationsarzneimittel enthaltend naloxone und ein opiatanalgetikum
US6559158B1 (en) 1997-11-03 2003-05-06 Ur Labs, Inc. Use of methylnaltrexone and related compounds to treat chronic opioid use side affects
US6274591B1 (en) 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
US20030158220A1 (en) 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
US5972954A (en) 1997-11-03 1999-10-26 Arch Development Corporation Use of methylnaltrexone and related compounds
GB0100115D0 (en) 2001-01-04 2001-02-14 Alchemia Pty Ltd Delivery systems
DE60238756D1 (de) * 2001-05-11 2011-02-10 Endo Pharmaceuticals Inc Opioid enthaltende arzneiform gegen missbrauch
EP1404323B1 (en) 2001-06-05 2009-10-28 The University of Chicago Use of methylnaltrexone to treat immune suppression
EP1436012B1 (en) 2001-10-18 2017-12-20 Nektar Therapeutics Polymer conjugates of opioid antagonists
WO2003048153A1 (en) * 2001-11-29 2003-06-12 Schering Corporation Process for the preparation of compositions having an increased amount of pharmaceutically active salts of rotamers
WO2003077867A2 (en) 2002-03-14 2003-09-25 Euro-Celtique, S.A. Naltrexone hydrochloride compositions
US20030191147A1 (en) 2002-04-09 2003-10-09 Barry Sherman Opioid antagonist compositions and dosage forms
CA2521369A1 (en) 2003-04-08 2004-10-28 Progenics Pharmaceuticals, Inc. The use of peripheral opiois antagonists, especially methylnaltrexone to treat irritable bowel syndrome
ES2528631T3 (es) 2003-04-08 2015-02-11 Progenics Pharmaceuticals, Inc. Formulaciones farmacéuticas que contienen metilnaltrexona
CA2521420A1 (en) * 2003-04-08 2004-10-28 Progenics Pharmaceuticals, Inc. Combination therapy for constipation comprising a laxative and a peripheral opioid antagonist
WO2005009356A2 (en) * 2003-07-15 2005-02-03 Pr Pharmaceuticals, Inc. Method for the preparation of controlled release formulations
US8946262B2 (en) 2003-12-04 2015-02-03 Adolor Corporation Methods of preventing and treating gastrointestinal dysfunction
JP2007514758A (ja) 2003-12-19 2007-06-07 シェーリング　コーポレイション 医薬組成物
DE602004031767D1 (de) * 2003-12-31 2011-04-21 Bend Res Inc Stabilisierte pharmazeutische feste zusammensetzungen von arzneimitteln mit geringer löslichkeit, poloxameren und stabilisierenden polymeren
CN1294728C (zh) 2004-08-05 2007-01-10 华为技术有限公司 边缘路由器提供服务质量保证的方法及系统
US20080103438A1 (en) 2004-09-30 2008-05-01 Prais Alfred W Method For Reducing Or Eliminating Residue In A Glass Container And A Glass Container Made In Accordance Therewith
US20060177380A1 (en) * 2004-11-24 2006-08-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
AR057035A1 (es) * 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
TWI489984B (zh) * 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
WO2008021394A2 (en) * 2006-08-15 2008-02-21 Theraquest Biosciences, Llc Pharmaceutical formulations of cannabinoids and method of use
CA2660100C (en) * 2006-08-16 2014-10-21 Novartis Ag Temporal photo-bleaching of colored lens care solutions and use thereof
JP2010506833A (ja) * 2006-10-11 2010-03-04 アルファーマ，インコーポレイテッド 医薬組成物
TW200843802A (en) 2007-02-09 2008-11-16 Drugtech Corp Compositions for improving gastrointestinal nutrient and drug absorption
ES2765811T5 (es) * 2007-03-29 2024-02-27 Progenics Pharm Inc Forma cristalina de bromuro de (R)-n-metilnaltrexona y sus usos
PL2565195T3 (pl) * 2007-03-29 2015-10-30 Wyeth Llc Obwodowy receptor opioidowy i jego antagoniści oraz ich zastosowania
JP5178064B2 (ja) * 2007-06-27 2013-04-10 富士フイルム株式会社 金属表面粗化層を有する金属層積層体及びその製造方法
EP2300009A1 (en) * 2008-05-07 2011-03-30 Nektar Therapeutics Oral administration of peripherally-acting opioid antagonists
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
JP5525247B2 (ja) * 2009-08-04 2014-06-18 株式会社神戸製鋼所 高強度で曲げ加工性に優れた銅合金
KR101913102B1 (ko) 2010-03-11 2018-10-31 와이어쓰 엘엘씨 메틸날트렉손의 경구 제형 및 친유성 염
TW201235609A (en) * 2010-07-13 2012-09-01 Koninkl Philips Electronics Nv Low cost mounting of LEDs in TL-retrofit tubes

Also Published As

Publication number Publication date
US20140249171A1 (en) 2014-09-04
KR101913102B1 (ko) 2018-10-31
US20190117646A1 (en) 2019-04-25
IL221452A (en) 2017-07-31
WO2011112816A1 (en) 2011-09-15
AU2011224275B2 (en) 2015-10-01
CA2789798A1 (en) 2011-09-15
EA201270741A1 (ru) 2013-02-28
PL2371357T3 (pl) 2017-09-29
SG183133A1 (en) 2012-09-27
UA111717C2 (uk) 2016-06-10
US20190314365A1 (en) 2019-10-17
US20130330407A1 (en) 2013-12-12
JP2016029054A (ja) 2016-03-03
CN107308125A (zh) 2017-11-03
HK1245673A1 (zh) 2018-08-31
MX349145B (es) 2017-07-14
JP2011190259A (ja) 2011-09-29
TN2012000392A1 (en) 2014-01-30
MX368805B (es) 2019-10-17
TW201622724A (zh) 2016-07-01
ES2623926T3 (es) 2017-07-12
US20120070495A1 (en) 2012-03-22
CN102918039A (zh) 2013-02-06
CN107308125B (zh) 2021-07-16
SG10201606618PA (en) 2016-09-29
US20190117645A1 (en) 2019-04-25
EP3178472A1 (en) 2017-06-14
TWI589293B (zh) 2017-07-01
ZA201808498B (en) 2019-08-28
GEP201606550B (en) 2016-10-10
KR101982482B1 (ko) 2019-05-27
US8956651B2 (en) 2015-02-17
AU2011224275A1 (en) 2012-08-23
MX2012009125A (es) 2012-09-07
NZ703564A (en) 2016-08-26
US20200121673A1 (en) 2020-04-23
TWI605814B (zh) 2017-11-21
KR20130010900A (ko) 2013-01-29
CN102918039B (zh) 2017-06-09
TW201141479A (en) 2011-12-01
NZ601595A (en) 2015-01-30
CA2789798C (en) 2020-09-22
UA123856C2 (uk) 2021-06-16
BR112012022873B1 (pt) 2021-09-14
US20160206612A1 (en) 2016-07-21
JP6429955B2 (ja) 2018-11-28
JP2017206553A (ja) 2017-11-24
US10507206B2 (en) 2019-12-17
ECSP12012208A (es) 2015-03-31
EP2371357B1 (en) 2017-02-01
EP3178472B1 (en) 2021-10-27
MA34146B1 (fr) 2013-04-03
US10376505B2 (en) 2019-08-13
JP6143409B2 (ja) 2017-06-07
EP2371357A1 (en) 2011-10-05
CL2012002192A1 (es) 2012-09-28
US9314461B2 (en) 2016-04-19
PE20130063A1 (es) 2013-02-11
EA029096B1 (ru) 2018-02-28
HUE033133T2 (en) 2017-11-28
NZ702826A (en) 2016-08-26
US10307417B2 (en) 2019-06-04
CO6630134A2 (es) 2013-03-01
US8524276B2 (en) 2013-09-03
MY160727A (en) 2017-03-15
BR112012022873A2 (pt) 2016-08-30
IL221452A0 (en) 2012-10-31
AR080491A1 (es) 2012-04-11
GT201200247A (es) 2013-09-11
JP2019034958A (ja) 2019-03-07
PH12012501622A1 (en) 2012-11-05
SG10201501821RA (en) 2015-05-28
KR20180118260A (ko) 2018-10-30
PL3178472T3 (pl) 2022-02-14
JP6647368B2 (ja) 2020-02-14

Similar Documents

Publication Publication Date Title
ECSP12012208A (es) Formulaciones orales y sales lipofílicas de metilnaltrexona
CY1122786T1 (el) Δοσολογικα σχηματα για ενωσεις κατηγοριας εχινοκανδινης
CO7091182A2 (es) Inhibidores de beta-lactamasa isoxazol
HN2011003371A (es) Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17
ECSP14007644A (es) Composiciones intranasales de dexmedetomidina y métodos de uso de ellas
CR20110110A (es) Composicion farmaceutica
CR20130406A (es) Composiciones farmacéuticas que comprenden anticuerpos humanos frente a pcsk9
ECSP13011139A (es) Anticuerpos contra la angiopoyetina 2 humana
HUE046557T2 (hu) Tapentadolt tartalmazó vizes gyógyszerészeti készítmény szájon át alkalmazásra
ECSP11011391A (es) Métodos y productos intermedios para preparar agentes farmacéuticos
CL2011000481S1 (es) Aplicador para cuidado oral.
CR10505A (es) Aminopirazolopiridinas sustituidas y sus sales, sus preparaciones y composiciones farmaceuticas que las comprenden
BR112012032008A2 (pt) anticorpos s100a4 e usos terapêuticos do mesmo
MX374468B (es) Composicion farmaceutica acuosa semisolida que contiene tapentadol.
BR112013008601A2 (pt) formulações de emulsão de clevidipina contendo agentes antimicrobianos
MX340983B (es) Composiciones farmaceuticas y nutraceuticas de acido abscisico.
CO6650346A2 (es) Composiciones de tetraciclina
MX2013006644A (es) Formulacion farmaceutica novedosa que comprende nsaid y ciclodextrina.
ECSP10010576A (es) Formulaciones orales e inyectables de compuestos de tetraciclina
BR112013019518A2 (pt) composições para cuidado oral.
ITTO20111220A1 (it) Composizione contenente un fosfato di tocoferolo e procedimento di preparazione.
CY1118277T1 (el) Σταθερη φαρμακοτεχνικη μορφη πεξιγανανης
BR112015012824A2 (pt) composições e métodos para tratar cáries dentárias
CO6720980A2 (es) Composiciones bucales
BR112015004115A2 (pt) composições farmacêuticas compreendendo flurbiprofeno